AnteoBind order received and Life Sciences Update
Filed with ASX · · 4 pages · English
Summary by 6ix AI
AnteoTech Ltd has announced the receipt of an order from the Serum Institute of India, marking progress in its Life Sciences business. The order is part of a five-year supply agreement and includes the evaluation of a new product prototype for ELISA development. The company has also reported growth in its sales pipeline, with new evaluations initiated across multiple regions. AnteoTech's strategy focuses on enhancing customer engagement and expanding its market presence in the life sciences sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AnteoTech
- Ultranode X achieves more than 1,000 Cycles at 80% Capacity
- Joint Development and Sales Agreement Executed
- Full Year Results and Business Update Presentation
- FY2025 Full Year Appendix 4E and Annual Report
- Appointment of MD & CEO and Annual Staff Review Process
Later from AnteoTech
- Trading Halt
- AnteoTech $3.5m Capital Raising
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Ultranode 95 validated in cell format suited for drone use
Follow AnteoTech into a list and get an email when it puts out news.
Follow AnteoTech